11/20
05:31 pm
vrna
Chronic Refractory Cough Market Still Unexplored, with Pharma Companies Eyeing First-Mover Advantage in the US | DelveInsight
Low
Report
Chronic Refractory Cough Market Still Unexplored, with Pharma Companies Eyeing First-Mover Advantage in the US | DelveInsight
11/20
05:31 pm
vrna
Chronic Refractory Cough Market Still Unexplored, with Pharma Companies Eyeing First-Mover Advantage in the US | DelveInsight
Low
Report
Chronic Refractory Cough Market Still Unexplored, with Pharma Companies Eyeing First-Mover Advantage in the US | DelveInsight
11/19
02:08 am
vrna
Verona Pharma Announces December 2024 Investor Conference Participation [Yahoo! Finance]
Medium
Report
Verona Pharma Announces December 2024 Investor Conference Participation [Yahoo! Finance]
11/19
02:00 am
vrna
Verona Pharma Announces December 2024 Investor Conference Participation
Medium
Report
Verona Pharma Announces December 2024 Investor Conference Participation
11/14
03:12 am
vrna
Actimed Therapeutics Announces Professor David Ebsworth to Become Executive Chairman [Yahoo! Finance]
Medium
Report
Actimed Therapeutics Announces Professor David Ebsworth to Become Executive Chairman [Yahoo! Finance]
11/14
03:00 am
vrna
Actimed Therapeutics Announces Professor David Ebsworth to Become Executive Chairman
Medium
Report
Actimed Therapeutics Announces Professor David Ebsworth to Become Executive Chairman
11/12
05:31 pm
vrna
Sanofi/Regeneron Pharmaceuticals' DUPIXENT Approval Marks a Significant Shift in Chronic Obstructive Pulmonary Disease Treatment Landscape | DelveInsight
Medium
Report
Sanofi/Regeneron Pharmaceuticals' DUPIXENT Approval Marks a Significant Shift in Chronic Obstructive Pulmonary Disease Treatment Landscape | DelveInsight
11/12
05:31 pm
vrna
Sanofi/Regeneron Pharmaceuticals' DUPIXENT Approval Marks a Significant Shift in Chronic Obstructive Pulmonary Disease Treatment Landscape | DelveInsight
Medium
Report
Sanofi/Regeneron Pharmaceuticals' DUPIXENT Approval Marks a Significant Shift in Chronic Obstructive Pulmonary Disease Treatment Landscape | DelveInsight
11/9
08:23 am
vrna
Caligan picks up a stake in Verona Pharma, seeing an opportunity to generate more value [CNBC]
Medium
Report
Caligan picks up a stake in Verona Pharma, seeing an opportunity to generate more value [CNBC]
11/8
06:44 am
vrna
Metered Dose Inhaler Devices Pipeline Market Research Report: Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2024 Update [Yahoo! Finance]
Low
Report
Metered Dose Inhaler Devices Pipeline Market Research Report: Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2024 Update [Yahoo! Finance]
11/7
05:31 pm
vrna
Global Respiratory Disease Testing Market to Grow at a CAGR of ~4% by 2030 | DelveInsight
Low
Report
Global Respiratory Disease Testing Market to Grow at a CAGR of ~4% by 2030 | DelveInsight
11/7
05:31 pm
vrna
Global Respiratory Disease Testing Market to Grow at a CAGR of ~4% by 2030 | DelveInsight
Low
Report
Global Respiratory Disease Testing Market to Grow at a CAGR of ~4% by 2030 | DelveInsight
11/5
10:41 am
vrna
Verona Pharma plc (NASDAQ: VRNA) had its price target raised by analysts at Wells Fargo & Company from $50.00 to $64.00. They now have an "overweight" rating on the stock.
Low
Report
Verona Pharma plc (NASDAQ: VRNA) had its price target raised by analysts at Wells Fargo & Company from $50.00 to $64.00. They now have an "overweight" rating on the stock.
11/5
09:43 am
vrna
Verona Pharma plc (NASDAQ: VRNA) had its price target raised by analysts at HC Wainwright from $36.00 to $42.00. They now have a "buy" rating on the stock.
Low
Report
Verona Pharma plc (NASDAQ: VRNA) had its price target raised by analysts at HC Wainwright from $36.00 to $42.00. They now have a "buy" rating on the stock.
11/5
08:17 am
vrna
Verona Pharma plc (NASDAQ: VRNA) had its price target raised by analysts at Canaccord Genuity Group Inc. from $37.00 to $44.00. They now have a "buy" rating on the stock.
Low
Report
Verona Pharma plc (NASDAQ: VRNA) had its price target raised by analysts at Canaccord Genuity Group Inc. from $37.00 to $44.00. They now have a "buy" rating on the stock.
11/5
02:14 am
vrna
Verona Pharma PLC (VRNA) Q3 2024 Earnings Call Highlights: Strong Ohtuvayre Launch Amid Rising Costs [Yahoo! Finance]
Low
Report
Verona Pharma PLC (VRNA) Q3 2024 Earnings Call Highlights: Strong Ohtuvayre Launch Amid Rising Costs [Yahoo! Finance]
11/5
02:00 am
vrna
Verona Pharma to Present at Jefferies London Healthcare Conference
Low
Report
Verona Pharma to Present at Jefferies London Healthcare Conference
11/4
02:10 am
vrna
Verona Pharma reports Q3 results Nov. 04, 2024 2:06 AM ET By: Manshi Mamtora , CFA [Seeking Alpha]
Medium
Report
Verona Pharma reports Q3 results Nov. 04, 2024 2:06 AM ET By: Manshi Mamtora , CFA [Seeking Alpha]
11/4
02:00 am
vrna
Verona Pharma Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Medium
Report
Verona Pharma Reports Third Quarter 2024 Financial Results and Provides Corporate Update
10/21
02:00 am
vrna
Verona Pharma to Report Third Quarter 2024 Financial Results and Provide Corporate Update
Low
Report
Verona Pharma to Report Third Quarter 2024 Financial Results and Provide Corporate Update
10/9
12:31 pm
vrna
Verona Pharma plc (NASDAQ: VRNA) had its price target raised by analysts at Truist Financial Co. from $38.00 to $44.00. They now have a "buy" rating on the stock.
Low
Report
Verona Pharma plc (NASDAQ: VRNA) had its price target raised by analysts at Truist Financial Co. from $38.00 to $44.00. They now have a "buy" rating on the stock.
10/8
05:00 am
vrna
Virometix appoints Christina Ackermann as Chair and Tim Ramdeen as member of the Board
Low
Report
Virometix appoints Christina Ackermann as Chair and Tim Ramdeen as member of the Board
10/3
12:22 pm
vrna
Verona started at overweight by Wells Fargo, says COPD drug undervalued [Seeking Alpha]
Low
Report
Verona started at overweight by Wells Fargo, says COPD drug undervalued [Seeking Alpha]
10/3
08:17 am
vrna
Verona Pharma plc (NASDAQ: VRNA) is now covered by analysts at Wells Fargo & Company. They set an "overweight" rating and a $50.00 price target on the stock.
Medium
Report
Verona Pharma plc (NASDAQ: VRNA) is now covered by analysts at Wells Fargo & Company. They set an "overweight" rating and a $50.00 price target on the stock.
10/1
08:01 am
vrna
Verona Pharma plc (NASDAQ: VRNA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $36.00 price target on the stock.
Medium
Report
Verona Pharma plc (NASDAQ: VRNA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $36.00 price target on the stock.